The cost effectiveness of combination antiretroviral therapy for HIV disease

New England Journal of Medicine

Volumn 344, Issue 11, 2001, Pages 824-831

  Freedberg, Kenneth A ^a,b,c   Losina, Elena ^a,b   Weinstein, Milton C ^c   Paltiel, A David ^f   Cohen, Calvin J ^e   Seage, George R ^d   Craven, Donald E ^b,g   Zhang, Hong ^a   Kimmel, April D ^a   Goldie, Sue J ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD CENTER FOR RISK ANALYSIS   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e Boston Community Research Initiative of New England   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; LYMPHOCYTE COUNT; MATHEMATICAL MODEL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SIMULATION; UNITED STATES;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DIRECT SERVICE COSTS; DISEASE PROGRESSION; DRUG COSTS; DRUG THERAPY, COMBINATION; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; LIFE EXPECTANCY; MODELS, BIOLOGICAL; QUALITY-ADJUSTED LIFE YEARS; RNA, VIRAL; UNITED STATES; VALUE OF LIFE;

EID: 0035869435     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200103153441108     Document Type: Article

References (46)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
2. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS trial: Italy, the Netherlands, Canada and Australia Study
3. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
4. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescent
5. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
6. The care of HIV-infected adults in the United States
7. Estimating the national cost of treating people with HIV disease: Patient, payer, and provider data
8. Combination antiretroviral therapy in HIV infection: An economic perspective
9. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients: Swiss HIV Cohort Study
10. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: Application to a clinical trial
11. Cost effectiveness of combination HIV therapy: 3 Years later
12. Protease inhibitor-based therapy is associated with decreased HIV-related health care costs in men treated at a Veterans Administration hospital
13. Impact of newer antiretroviral (ARV) therapies on inpatient and outpatient utilization of healthcare resources in patients with HIV
14. Impact of combination therapy for HIV infection on inpatient census
15. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
16. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
17. The cost-effectiveness of preventing AIDS-related opportunistic infections
18. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
19. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy
20. Withdrawal of prophylaxis against Pneumocystis carinii pneumonia
21. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy
22. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-Week follow-up
23. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
24. A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons: Terry Beirn Community Programs for clinical Research on AIDS
25. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both
26. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS
27. Estimability and estimation in case-referent studies
28. Random-effects models for longitudinal data
29. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA)
30. The distinction between cost and charges
31. Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols
32. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs
33. Social preferences for health states: An empirical evaluation of three measurement techniques
34. 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine
35. Gains in life expectancy from medical interventions - Standardizing data on outcomes
36. Threshold analysis and programs for prevention of HIV infection
37. Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer
38. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease
39. Outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults